Skip to main content

Table 1 Characteristics of patients

From: Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China

Parameter Total KTX-HD KTX
DAA-KTX KTX-DAA
Patients 26 11 7 8
Age, years [mean ± SD] 49.0 ± 9.6 52.6 ± 10.0 39.7 ± 5.5 52.1 ± 6.6
Gender (male) [n (%)] 19 (73.1) 8 (72.7) 5 (71.4) 6 (75.0)
Transplant frequency [n (%)]
 1 12 (46.2) 6 (54.5) 2 (28.6) 4 (50.0)
 2 12 (46.2) 5 (45.5) 4 (57.1) 3 (37.5)
 ≥3 2 (7.7) 0 (0.0) 1 (14.3) 1 (12.5)
HCV genotype [n (%)]
 1b 21 (80.8) 10 (90.9) 5 (71.4) 6 (75.0)
 2a 5 (19.2) 1 (9.1) 2 (28.6) 2 (25.0)
 Cirrhosis [n (%)] 1 (3.8) 0 (0.0) 0 (0.0) 1 (12.5)
Immunosuppressive regimens [n (%)]
 Triple-therapy 18 (69.2) 3 (27.3) 7 (100.0) 8 (100.0)
 Double-therapy 6 (23.1) 6 (54.5) 0 (0.0) 0 (0.0)
 Monotherapy 2 (7.7) 2 (18.2) 0 (0.0) 0 (0.0)
DAAs regimens [n (%)]
 SOF 1 (3.8) 0 (0.0) 1 (14.3) 0 (0.0)
 SOF + LDV 17 (65.4) 8 (72.7) 4 (57.1) 5 (62.5)
 SOF + DCV 8 (30.8) 3 (27.3) 2 (28.6) 3 (37.5)
 Viral load, log10 IU/ml [mean ± SD] 6.5 ± 1.3 5.9 ± 1.1 6.5 ± 0.5 7.2 ± 1.6
 Treatment cycle, weeks [median (range)] 12 (12-12) 12 (12-12) 12 (12-12) 12 (12-24)